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End-organ impairment has received relatively little research 
attention as a possible manifestation of tuberculosis immune 
reconstitution inflammatory syndrome (TB-IRIS). In this pro-
spective cohort study, one-half of adults with human immu-
nodeficiency virus and pulmonary tuberculosis experienced 
meaningful declines in lung function on antiretroviral therapy, 
suggesting a role for lung function in TB-IRIS definitions.
Keywords. tuberculosis; HIV; immune reconstitution in-
flammatory syndrome; pulmonary function.  
Tuberculosis (TB) remains the number one cause of death 
of people with human immunodeficiency virus (HIV) [1]. 
Initiating antiretroviral therapy (ART) during TB treatment de-
creases mortality in adults with HIV and TB, but can trigger 
the immune reconstitution inflammatory syndrome (IRIS) 
[2]. Using standard clinical definitions, TB-IRIS is reported to 
occur in approximately 20% of those initiating ART during TB 
treatment, often involves the lungs, and is driven in part by im-
mune restoration to mycobacterial antigens [2].
Approximately one-half of HIV-negative adults cured of pul-
monary TB have chronic lung impairment, and there is growing 
recognition of the global burden of respiratory disability fol-
lowing TB cure [3]. In people with HIV and TB coinfection, 
pulmonary inflammation from ART-mediated immune resto-
ration may provoke additional lung damage, but there are lim-
ited data on lung function trajectories following ART initiation. 
Thus, we sought to determine the incidence of, risk factors for, 
and long-term impact of clinically meaningful lung function 
declines in adults initiating ART during TB treatment.
METHODS
We conducted a prospective cohort study enrolling ART-naive 
adults living with HIV with CD4 counts ≤500 cells/μL and 
GeneXpert-positive, rifampicin-susceptible pulmonary TB in 
Gauteng, South Africa, during 2016–2019. All participants ini-
tiated efavirenz, emtricitabine, and tenofovir during the inten-
sive phase of short-course TB therapy. Lung function tests were 
conducted prior to (baseline) and at 4, 12, 24, and 48 weeks 
after ART initiation; participants completed at least 2 lung 
function tests in the first 12 weeks. Forced expiratory volume 
in 1 second (FEV1) and forced vital capacity were measured 
with an EasyOne Pro Spirometer (ndd Medical Technologies, 
Andover, Massachusetts) as absolute volumes (mL) and per-
centage of predicted values (ie, referenced to age, sex, height, 
and race). Respiratory symptoms were assessed using the 
Chronic Obstructive Pulmonary Disease Assessment Test 
(CAT), and the 6-minute walk test (6MWT) was administered 
as a submaximal exercise test of pulmonary disability [4, 5]. 
CD4 count and HIV viral load were measured at baseline and 
week 4 of ART. Paradoxical TB-IRIS was identified at monthly 
visits using the Meintjes et al criteria [2].
We identified participants with an FEV1 decline of ≥100 mL, 
the minimum clinically important difference in other pul-
monary diseases [6], during the first 12 weeks after ART ini-
tiation. Those with a ≥100 mL decline were then divided into 
tertiles according to the amount of decline. We compared 
sociodemographic and clinical characteristics of participants 
with and without lung function declines using the χ 2 or Kruskal-
Wallis test. Multivariate logistic regression was used to deter-
mine the association between an FEV1 decline ≥100 mL in the 
first 12 weeks and impaired lung function at the end of TB treat-
ment, which we defined as an FEV1 <80% predicted at the latter 
available of the 24- or 48-week visit (ie, the “final” lung function 
measurement). We examined the following variables for effect 
modification or confounding: age, sex, smoking status, time to 
ART initiation, baseline CD4 count and viral load, and baseline 
FEV1. Covariates were included in the final model based on a 
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priori knowledge or a bivariate association with final FEV1 with 
a P value <.2. Analyses were conducted in SAS version 9.4 soft-
ware (SAS Institute, Cary, North Carolina).
RESULTS
Participant sociodemographic and clinical characteristics 
are shown in Table 1. Among 101 participants with at least 2 
lung function measurements in the first 12 weeks of ART, half 
(50 [50%]) had a clinically significant FEV1 decline of at least 
100  mL after ART initiation. After dividing those 50 partici-
pants into tertiles, 16 (16%) participants had a mild FEV1 drop 
of 100–299 mL, 16 (16%) had a moderate drop of 300–599 mL, 
and 18 (18%) had a severe drop of ≥600  mL, with a median 
FEV1 drop of 955  mL (interquartile range, 840–1240  mL) in 
these individuals. No participants had evidence of HIV treat-
ment failure, and all successfully completed TB treatment.
An FEV1 drop of at least 100  mL on ART was significantly 
associated with a longer 6MWT distance and higher FEV1 at 
baseline, but not with other characteristics either at baseline or 
after ART initiation, including sputum culture status and time 
to culture positivity in liquid media (Table 1 and Figure 1). 
Although there was no significant difference in the final FEV1 
for those with and without lung function declines, a significantly 
greater proportion of those with severe declines (ie, FEV1 drop 
≥600  mL) had a final FEV1 <80% predicted, compared with 
Table 1. Clinical Characteristics According to the Presence or Absence of Pulmonary Immune Reconstitution Inflammatory Syndrome (IRIS) and Degree 
of Pulmonary IRIS
Characteristica
No Lung Function 
Decline
Lung Function  
Decline P Valueb
Mild Lung  
Function Decline
Moderate Lung 
Function Decline
Severe Lung  
Function Decline
(n = 51) (n = 50)  (n = 16) (n = 16) (n = 18)
Baseline characteristics       
 Age, y, mean (range) 36 (31–41) 36 (31–45) > .5 36 (29–44) 36 (30–45) 36 (32–47)
 Female sex 25 (49) 19 (38) .26 8 (50) 7 (44) 4 (22)
 Current smoker 5 (10) 10 (20) .15 3 (19) 4 (25) 3 (17)
 Time to ART initiation after 
TB treatment initiation, d
22 (16–38) 27 (15–47) > .5 24 (16–32) 20 (14–47) 31 (23–49)
 CD4 count, cells/μL 106 (48–204) 110 (51–182) > .5 160 (66–274) 87 (20–133) 108 (51–180)
 Log10 plasma HIV-1, 
copies/mL
5.1 (4.7–5.7) 5.3 (4.9–5.8) .30 5.2 (4.8–5.5) 5.3 (5.0–5.7) 5.4 (5.0–5.8)
 Sputum culture positive at 
baseline visit
24 (47) 21 (42) > .5 7 (44) 7 (44) 7 (39)
 Time to sputum culture  
positivity in liquid media 
among culture-positive  
samples, d
13 (9–15) 14 (12–18) > .5 14 (12–16) 18 (13–18) 12 (9–17)
 CAT score 5 (3–12) 5.5 (2–11) .47 3 (1–11) 6.5 (1.5–9) 8 (4–12)
 6MWT, m 368 (328–430) 408 (361–456) .05 432 (362–479) 403 (312–456) 406 (368–449)
 FEV1 % predicted 71 (58–84) 82 (75–95) < .001 81 (76–94) 86 (76–102) 82 (67–95)
 FEV1 <80% predicted 34 (67) 19 (38) .004 6 (38) 5 (31) 8 (44)
Early change from baseline to 4 wk      
 Increase in CD4 count, 
cells/μL
65 (26–106) 69 (25–172) .36 51 (24–169) 79 (32–172) 64 (34–170)
 Decrease in log VL 5.1 (4.7–5.6) 5.2 (4.7–5.6) > .5 5.2 (4.6–5.5) 5.2 (4.6–5.5) 5.2 (4.9–5.7)
 Change in CAT score 0 (−2 to 1) 0 (−1 to 2) .44 0 (−1 to 1) 0.5 (−2.5 to 3.5) −1 (−3 to 3)
 Change in 6MWT, m −12 (−48 to 22) −27 (−60 to 7) .19 −37 (−79 to 4) −43 (−72 to −12) −10 (−34 to 12)
 Change in FEV1, mL
c 100 (−20 to 270) −500 (−870 to −210) < .001 −155 (−205 to −130) −495 (−530 to −375) −955 (−1240 to −850)
Final characteristics       
 Final FEV1% predicted
d 83 (68–90) 82 (73–93) > .5 86 (77–92) 86 (77–100) 73 (67–83)
 Final FEV1 <80%  
predicted
15 (39) 20 (47) > .5 5 (36) 5 (33) 10 (71)
 Change in FEV1, mL,  
baseline to final
400 (60–660) −10 (−350 to 310) .01 170 (−110 to 310) 0 (−190 to 230) −375 (−540 to 580)
Mild pulmonary TB immune reconstitution inflammatory syndrome (IRIS) is defined as initial FEV1 decline of 100-299 mL; moderate pulmonary TB-IRIS is defined as initial FEV1 decline of 
300-599 mL; and severe pulmonary TB-IRIS is defined as initial FEV1 decline of ≥600 mL. P values ≤.05 are in bold.
Abbreviations: 6MWT, 6-minute walk test; ART, antiretroviral therapy; CAT, Chronic Obstructive Pulmonary Disease Assessment Test; FEV1, forced expiratory volume in 1 second; HIV-1, 
human immunodeficiency virus type 1; TB, tuberculosis; VL, viral load.
aUnless otherwise indicated, continuous variables are expressed as median (interquartile range) and categorical variables are expressed as No. (%).
bP values compare those with and without pulmonary IRIS, using χ 2 test for categorical variables and Kruskal-Wallis test for continuous variables.
cChange in FEV1 included change during baseline to 12 weeks, as explained in the Methods.
dFinal values were available for 81 participants (38 no IRIS; 43 IRIS [14 mild, 15 moderate, 14 severe]) based on week 24 values for 30 participants and week 48 values for 51 participants.
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those without a decline (71% vs 39%; P  =  .04). Furthermore, 
after adjustment for age, sex, time from TB treatment to ART 
initiation, baseline CD4 count, and baseline FEV1, those with 
FEV1 drops of any severity had >7 times the odds of having a 
final FEV1 <80% predicted compared with those without an 
early FEV1 drop (odds ratio, 7.59 [95% confidence interval, 
1.67–34.63]). This significantly increased risk of a final FEV1 
<80% predicted seen after adjustment for baseline factors, no-
tably the baseline FEV1, parallels the trends in Figure 1A and 1B, 
whereby those who developed lung function declines typically 
started with higher lung function but had less recovery of lung 
function during treatment. All participants had improvements 
in their symptom scores, and most had accompanying improve-
ments in their 6MWT.
Six participants met standard definitions for TB-IRIS [2], 
5 of whom had qualifying spirometry. One had respiratory 
symptoms but did not experience a decline in lung function 
(Supplementary Table).
DISCUSSION
In this prospective cohort study, approximately half of those 
with pulmonary TB initiating ART experienced FEV1 de-
clines of a magnitude considered clinically significant in other 
pulmonary diseases [6], and 18% had severe FEV1 drops asso-
ciated with lung function that remained depressed at TB treat-
ment completion, when impairment may be permanent [7]. 
These findings are important because decreased lung func-
tion is associated with increased mortality in people with and 
without overt pulmonary disease [8].
Patients whose lung function declined on ART experienced 
these declines within the first 3 months of ART initiation, com-
pleted TB treatment without evidence of microbiological failure, 
had no newly diagnosed pulmonary infections, and had substan-
tial virologic decreases and CD4 increases on ART, consistent 
with standard definitions of paradoxical TB-IRIS [2, 9, 10]. 
Furthermore, the finding that less lung involvement at baseline 
was associated with an increased risk of lung function decline 
after starting ART is consistent with findings from a subset of this 
cohort, indicating that less pulmonary radiographic inflamma-
tion at baseline is associated with greater increases in lung in-
flammation during the initial weeks of ART [11]. Nonetheless, 
the lack of association between both bacterial burden and timing 
of ART initiation with declines in lung function contrasts with 
the concept that greater antigen burden drives TB-IRIS risk. 
Furthermore, TB progression despite TB treatment and ART ini-
tiation, drug toxicity, and undiagnosed pulmonary opportunistic 
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Figure 1. Lung function, pulmonary symptoms, and functional capacity over time. A, Predicted percentage of forced expiratory volume in 1 second (FEV1). B, FEV1 change 
from baseline. C, Chronic Obstructive Pulmonary Disease Assessment Test score. D, Six-minute walk test. Abbreviations: ART, antiretroviral therapy; CAT, Chronic Obstructive 
Pulmonary Disease Assessment Test; FEV1, forced expiratory volume in 1 second.
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illnesses cannot be excluded as possible contributors to the lung 
function declines we identified. Additional research is needed.
Lung function declines were not always symptomatic and 
may not be detected by routine TB-IRIS surveillance unless 
spirometry is performed. Our findings require validation, but 
suggest that otherwise unexplained drops in pulmonary func-
tion on ART warrant consideration as an additional criteria 
for a TB-IRIS diagnosis. In the definition used in this study, if 
lung function declines were considered “focal tissue involve-
ment” (as per the Meintjes et al [2] definition), the incidence 
of IRIS would have increased considerably. Major lung func-
tion declines on ART could also be considered a manifestation 
of a “clinical course not consistent with the expected course of 
TB” to fulfill the definition of French et al [10], or could have 
spirometry added to radiography as a sign of worsening di-
sease in the TB-IRIS–specific definition of Colebunders et  al 
[9]. This functional definition of pulmonary TB-IRIS could 
help identify those experiencing incident pulmonary damage 
on ART [2]. Lung function declines of a magnitude associated 
with greater longer-term pulmonary impairment (eg, in this 
study, ≥600 mL) may merit a TB-IRIS diagnosis. Failure to im-
prove from baseline, when acute TB-associated inflammation is 
present, to end of therapy was also common in this study and 
merits consideration as an IRIS criterion.
We were unable to conduct prediagnosis pulmonary function 
testing, nor did we have baseline and follow-up chest radiog-
raphy. Our sample size also limits our ability to examine all risk 
factors of interest. Nevertheless, our data suggest that people 
with HIV and TB are at risk of incident lung damage following 
ART initiation. A recent randomized clinical trial demonstrated 
that corticosteroid use at the time of ART initiation decreased 
TB-IRIS risk in adults and that these or other anti-inflamma-
tory therapies may improve pulmonary outcomes in this pop-
ulation [12]. Inhaled corticosteroids, which specifically target 
inflammation in the lungs, present another potential interven-
tion. Preclinical data also indicate that novel agents, such as 
phosphodiesterase-4 and matrix metalloproteinase inhibitors, 
reduce lung involvement in small-animal models of TB [13, 
14]. The majority of TB-related disease burden, as measured in 
disability-adjusted life-years, is due to pulmonary impairment 
after treatment completion [15]. Therefore, patients with HIV/
TB may benefit from research on interventions to preserve lung 
function and prevent chronic pulmonary impairment on ART.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
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so questions or comments should be addressed to the corresponding author.
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